MENU

Adaptimmune Therapeutics plc - American Depositary Shares (NQ:ADAP)

0.1400 -0.0070 (-4.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2025 Add to My Watchlist

Price and Volume

Detailed Quote
Volume 46,154,197
Open 0.1574
Bid (Size) 0.1410 (50)
Ask (Size) 0.1438 (29)
Prev. Close 0.1470
Today's Range 0.1349 - 0.1649
52wk Range 0.0403 - 1.000
Shares Outstanding 1,535,653,620
Dividend Yield N/A

Performance

YTD
-77.5%
-77.5%
1 Month
+137.7%
+137.7%
3 Month
-41.6%
-41.6%
6 Month
-28.9%
-28.9%
1 Year
-85.3%
-85.3%

More News

Read More

Frequently Asked Questions

Is Adaptimmune Therapeutics plc - American Depositary Shares publicly traded?
Yes, Adaptimmune Therapeutics plc - American Depositary Shares is publicly traded.
What exchange does Adaptimmune Therapeutics plc - American Depositary Shares trade on?
Adaptimmune Therapeutics plc - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Adaptimmune Therapeutics plc - American Depositary Shares?
The ticker symbol for Adaptimmune Therapeutics plc - American Depositary Shares is ADAP on the Nasdaq Stock Market
What is the current price of Adaptimmune Therapeutics plc - American Depositary Shares?
The current price of Adaptimmune Therapeutics plc - American Depositary Shares is 0.1400
When was Adaptimmune Therapeutics plc - American Depositary Shares last traded?
The last trade of Adaptimmune Therapeutics plc - American Depositary Shares was at 09/29/25 04:00 PM ET
What is the market capitalization of Adaptimmune Therapeutics plc - American Depositary Shares?
The market capitalization of Adaptimmune Therapeutics plc - American Depositary Shares is 214.99M
How many shares of Adaptimmune Therapeutics plc - American Depositary Shares are outstanding?
Adaptimmune Therapeutics plc - American Depositary Shares has 215M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
TOP
Email a Story